CBD and Epilepsy: A Brain Composed of Cannabis Leaves

CBD and Epilepsy: What the Latest Research Reveals

Mira Elwood monogram
Mira Elwood in Health & Wellness November 2026 • 4 min read.

"A comprehensive look at the efficacy, safety, and drug interactions of cannabidiol (CBD) in treating refractory epilepsy, offering insights for patients and clinicians."


Epilepsy, a neurological disorder characterized by recurrent seizures, affects millions worldwide. For approximately one-third of these individuals, seizures remain uncontrolled despite trying multiple anti-epileptic drugs (AEDs). This condition, known as treatment-resistant epilepsy (TRE), significantly impacts quality of life, increasing morbidity and mortality.

In recent years, cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, has garnered significant attention as a potential treatment for epilepsy, particularly TRE. Unlike its counterpart, tetrahydrocannabinol (THC), CBD does not produce the 'high' associated with cannabis use, making it an attractive option for patients and parents seeking alternative therapies.

Fueled by anecdotal evidence and increasing media coverage, interest in CBD has surged. However, it's crucial to differentiate between hype and scientifically-backed evidence. This article sifts through the latest research, examining the efficacy, safety, and potential drug interactions of CBD in treating epilepsy, providing a balanced and informed perspective.

AI Search Multiple angles on this topic

CBD and Epilepsy Today

Cannabidiol (CBD) is one of 113 identified cannabinoids in Cannabis and can account for up to 40% of the plant's extract, according to Wikipedia. It is described as an anticonvulsant used to treat two rare forms of childhood epilepsy. CBD is a cannabinoid alongside THC, but Healthline notes that it does not cause a high.

Products and Practical Limits

CBD.co presents CBD and THC products through an online retail model. Its listed product categories include edibles, THC vapes, and oils, with shipping offered through the site. This commercial source describes product access, but it does not establish which format is appropriate for epilepsy treatment or address clinical limitations.

Early Discovery

The historical record of CBD includes its discovery in 1940. Its role in epilepsy research developed over time, but the limited source material here does not establish a complete timeline of milestones. Any broader historical account would require additional sources.

CBD for Treatment-Resistant Epilepsy: What the Studies Say

CBD and Epilepsy: A Brain Composed of Cannabis Leaves

One of the most significant studies on CBD for TRE was an open-label interventional trial published in The Lancet Neurology in 2016. Led by Orrin Devinsky and colleagues, the study enrolled 214 patients aged 1-30 years with severe, intractable, childhood-onset, treatment-resistant epilepsy. Participants received oral CBD at a starting dose of 2-5 mg/kg per day, gradually increased to a maximum of 25 mg/kg or 50 mg/kg per day, depending on the study site.

The primary objective was to assess the safety and tolerability of CBD, with the primary efficacy endpoint being the median percentage change in the frequency of motor seizures after 12 weeks. The results showed that:

  • Adverse events were common, reported in 79% of patients, including somnolence (25%), decreased appetite (19%), diarrhea (19%), and fatigue (13%).
  • Serious adverse events occurred in 30% of patients, though only 12% were considered possibly related to CBD.
  • The median monthly frequency of motor seizures decreased by 36.5% over the 12-week treatment period.
AI Search Multiple angles on this topic

Current Evidence

Current research on CBD and epilepsy should be interpreted cautiously because the available material for this subsection does not identify particular studies or reviews. Evidence may differ by formulation, condition, and research design. A firm assessment of the latest findings would require study-specific sources.

Evidence Boundaries

The supplied material does not document specific failed trials, adverse findings, or arguments against CBD for epilepsy. It therefore cannot support a detailed account of treatment failures. Claims about effectiveness or limitations should be tied to directly reported clinical evidence.

Comparing Options

No source material provided here directly compares CBD with standard antiseizure medicines, other cannabinoids, or different CBD formulations. Any comparison would depend on outcomes, dosing, safety, and patient characteristics. Those details should not be inferred without comparative studies.

While the study lacked a placebo control, the findings suggested that CBD might reduce seizure frequency and have an acceptable safety profile in children and young adults with highly treatment-resistant epilepsy. The researchers emphasized the need for randomized controlled trials to further characterize the safety and efficacy of CBD.

The Future of CBD in Epilepsy Treatment

The research on CBD for epilepsy is still evolving, but the initial findings are promising. While CBD is not a cure for epilepsy, it may offer a valuable option for individuals with treatment-resistant seizures. As more rigorous studies are conducted, we will gain a better understanding of the optimal use of CBD, its potential benefits and risks, and its place in the comprehensive management of epilepsy.

AI Search Multiple angles on this topic

Balanced Interpretation

The supplied sources support viewing CBD as a cannabis-derived cannabinoid with an established place in discussion of two rare childhood epilepsies. They do not provide enough evidence for broad conclusions about every form of epilepsy or every CBD product. Expert interpretation should therefore distinguish specific medical uses from general commercial claims.

Research Ahead

Future work on CBD and epilepsy would benefit from clearer evidence about formulations, clinical outcomes, and longer-term safety. The provided material does not identify particular upcoming trials or research programs. Predictions about the field's next breakthroughs would therefore be speculative.

Access and Regulation

CBD's broader context includes the coexistence of medical interest and a commercial marketplace. The supplied retail source lists products such as edibles, THC vapes, and oils, but does not establish consistent medical quality or suitability. This gap highlights why access to products should not be treated as equivalent to evidence-based epilepsy care.

Patient Perspective

For families affected by rare childhood epilepsies, CBD may be relevant because it is described as an anticonvulsant for two such conditions. At the same time, the provided sources do not describe individual patient experiences, response rates, or quality-of-life outcomes. Personal treatment decisions therefore require clinical guidance rather than relying solely on general product information.

Seizure changes against placebo in Dravet and Lennox-Gastaut syndromes

  • −22.8 percentage pointsIn a Dravet syndrome trial, monthly convulsive seizures fell from a median of 12.4 to 5.9 with cannabidiol, compared with 14.9 to 14.1 with placebo. The adjusted difference between groups in change was −22.8 percentage points.[1]
  • 41.9%, 37.2%, 17.2% reduction from baselineFor Lennox–Gastaut syndrome, drop-seizure frequency fell 41.9% with 20-mg cannabidiol and 37.2% with 10-mg cannabidiol, compared with 17.2% with placebo.[2]

Questions the evidence leaves open

  • How should the seizure outcomes be weighed alongside the higher adverse-event frequency and liver-enzyme elevations reported in other evidence?[1] [3] [4]
  • Why did the transdermal focal-epilepsy trial show no significant separation from placebo, while oral-cannabidiol trials reported reductions for particular seizure outcomes? The excerpts describe different conditions and routes, but do not resolve the reasons for the differing results.[2] [5] [6]
  • What accounts for the variability in cannabidiol blood concentrations and individualized dosing described in the transdermal trial, and how does that variability affect interpretation of dose response?[6]
  • How might cannabidiol’s proposed effects on neuronal calcium movement and adenosine signalling relate to seizure suppression? The described mechanisms are presented as possibilities, not a settled explanation.[4]

Terms used in the evidence

Liver transaminases
The excerpt discusses transaminase concentrations and alanine aminotransferase as liver-enzyme measures.[4]
Adenosine
A signalling molecule described in the excerpt as having a role in seizure suppression.[4]

Sources

  1. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. (www.nejm.org)
  2. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. (www.nejm.org)
  3. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. (pubmed.ncbi.nlm.nih.gov)
  4. Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome) (pmc.ncbi.nlm.nih.gov)
  5. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome (pmc.ncbi.nlm.nih.gov)
  6. Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Treatment-Resistant Epilepsy (TRE), and why is it significant?

Treatment-Resistant Epilepsy (TRE) refers to a condition where seizures persist despite trying multiple anti-epileptic drugs (AEDs). This affects approximately one-third of individuals with epilepsy. TRE significantly impacts quality of life and increases morbidity and mortality. This makes the search for alternative treatments, such as cannabidiol (CBD), critical for these patients.

2

How does Cannabidiol (CBD) differ from Tetrahydrocannabinol (THC), and why is this difference important for epilepsy treatment?

Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant, unlike Tetrahydrocannabinol (THC). THC produces the 'high' associated with cannabis use. The absence of psychoactive effects makes CBD a more appealing option for patients, particularly children and young adults with epilepsy, and for their parents, who are seeking alternative therapies without the mind-altering effects. This distinction is crucial in the context of epilepsy treatment, where the goal is seizure control without impairing cognitive function or causing unwanted side effects.

3

What were the key findings of *The Lancet Neurology* study regarding CBD for Treatment-Resistant Epilepsy?

The open-label interventional trial published in *The Lancet Neurology* enrolled 214 patients aged 1-30 years with severe, intractable, childhood-onset, treatment-resistant epilepsy. The study used oral CBD, with dosages up to 25 mg/kg or 50 mg/kg per day. The results indicated that the median monthly frequency of motor seizures decreased by 36.5% over 12 weeks. Adverse events were common, with somnolence, decreased appetite, diarrhea, and fatigue being the most frequent. Serious adverse events were observed in 30% of patients, though most were not considered CBD-related. While lacking a placebo control, the findings suggested that CBD might reduce seizure frequency and have an acceptable safety profile.

4

What are the potential side effects of using CBD for epilepsy, as indicated by the research?

The research indicates that adverse events associated with CBD use are common. In the *The Lancet Neurology* study, 79% of patients reported adverse events. These included somnolence (25%), decreased appetite (19%), diarrhea (19%), and fatigue (13%). Serious adverse events occurred in 30% of the patients. It's important to note that, while adverse events were frequent, not all were directly attributed to CBD. Patients and clinicians should carefully weigh the potential benefits against these risks when considering CBD treatment.

5

What is the future of CBD in treating epilepsy, according to the available evidence?

The research on CBD for epilepsy is still evolving, but initial findings are promising. While CBD is not a cure, it may offer a valuable option for individuals with treatment-resistant seizures. As more rigorous studies are conducted, we will gain a better understanding of the optimal use of CBD, its potential benefits and risks, and its place in the comprehensive management of epilepsy. Further research is needed to fully characterize the safety and efficacy of CBD and to determine its optimal use in the treatment of epilepsy, including dosage, long-term effects, and potential drug interactions.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.